Trade Incyte Corporation - INCY shares price

1m
5m
15m
30m
1H
4H
1D
1W
Open on web platform

Market info

Min traded quantity:
1
Full name:
Incyte Corporation
Currency:
USD
Margin:
5%
Stock exchange:
United States of America
Long position overnight fee
-0.0203%
Short position overnight fee
-0.0102%

Trading hours (UTC)

Mon - Fri:
13:30 - 20:00

INCY

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States. It offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and ICLUSIG, a kinase inhibitor for the treatment of chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. The company's clinical stage products include ruxolitinib, a drug that is in pivotal Phase II clinical trial for steroid-refractory acute graft-versus-host-diseases (GVHD); and Phase II clinical trial for the treatment of essential thrombocythemia, as well as Phase III clinical trials for steroid-refractory acute and chronic GVHDs. In addition, it is developing itacitinib that is in Phase I/II clinical trial in combination with osimertinib for non-small cell lung cancer (NSCLC), as well as Phase III clinical trial for naïve acute GVHD; epacadostat that is in Phase III clinical trails for the treatment of melanoma, renal, bladder, head and neck, non-small cell lung cancers; MGA012 that is in Phase I clinical trial for solid tumors; INCB50465, which is in Phase II clinical trials for the treatment of diffuse large b-cell lymphoma, follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma; and INCB54828 that is in Phase II clinical trials for the bladder cancer, cholangiocarcinoma, and 8p11 myeloproliferative syndrome. The company markets its JAKAFI product through a network of specialty pharmacy providers and wholesalers. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; Pfizer; and MacroGenics, Inc. Incyte Corporation was founded in 1991 and is headquartered in Wilmington, Delaware.
White Paper Declaration

You might be interested in

A world first

Our advanced web platform is the world’s first regulated tokenised assets exchange.

Crypto as collateral

Trade the global financial markets using Bitcoin or Ethereum.

Security as priority

Authorised by the High Technology Park of Belarus, the European blockchain regulator, the safety of your holdings is guaranteed.

Technical indicators

Keep an eye on your positions with over 75 advanced charts, price analysis and price alerts.

Control your capital

Use stop-loss and take-profit orders to keep what you earn.

Use the world’s first regulated tokenised assets exchange to build a diverse investment portfolio with your crypto holdings. Make your deposits in Bitcoin or Ethereum to trade global financial instruments with competitive leverage and tight spreads. Currency.com keeps your holdings secure and accessible at a glance.

VISA MASTERCARD Yandex Money WIRE Faster payments SEPA PCI BTC ETH